
|Articles|January 1, 2004
Sweeping changes
Author(s)John Jesitus
Washington, D.C. - With a handful of new options expected to receive FDA approval within a year, the field of tissue augmentation stands poised to undergo a seismic shift. "The bottom line is, tissue augmentation is about to change dramatically," said Mariano E. Busso, M.D. He is clinical professor in the University of Miami's department of dermatology, chief of dermatology at Mercy Hospital, also in Miami, Fla., and a private practitioner who is board-certified in dermatology.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Accepts sBLA for OnabotulinumtoxinA in Masseter Muscle, Pursuing Fifth Aesthetic Indication
2
Zasocitinib Shows High Rates of Scalp Psoriasis Clearance Through Week 24
3
AAD Pediatric AD Guidelines Back Roflumilast, Ruxolitinib, Tapinarof
4
Modern Psoriasis Treatment: From Topicals to IL-23 and IL-17 Biologics
5











